** Shares of gene therapy developer Rocket Pharmaceuticals RCKT.O rise 1.8% to $3.42 premarket
** Company says it is reducing headcount by about 30% and its 12-month cash burn by nearly 25%
** Adds it is restructuring its drug development program to focus on its cardiovascular therapies and its main gene therapy candidate, kresladi, being developed for the treatment of a rare immunodeficiency disorder called severe leukocyte adhesion deficiency
** Up to last close, stock down 73.3% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。